Article

J&J Opens Doxil Rationing Program To New Patients

Johnson & Johnson (JNJ) will begin allowing new patients to enroll in a rationing program to receive the cancer drug Doxil because some of the limited, remaining supply has been freed up.

In a notice posted on the Doxil website Wednesday, J&J said it will reopen enrollment in the program starting Friday because some prior requests from doctors have changed and freed up supplies. Some doctors told J&J that Doxil supplies earmarked for patients already enrolled were no longer needed or they opted patients out of the program, the company said.

About 1,000 patients are now receiving Doxil--which treats ovarian and other cancers--through an allocation program that J&J created last year to address a product shortage.

Read the full story: http://hcp.lv/K6a9Bp

Source: Morningstar

Related Videos
Toby Maher, MD, PhD, professor of clinical medicine, Keck School of Medicine at USC
Nini Wu, MD, Navista
Fred Locke, MD, Moffitt Cancer Center and Research Institute
Dr Emma Achola-Kothari
Matthew Viggiano, MD, internal medicine resident, Temple University Hospital
1 expert in this video
1 expert in this video
Krunal Patel, MD, pulmonary and critical care fellow, Temple University Hospital
M. Bradley Drummond, MD, MHS, professor of medicine, University of North Carolina at Chapel Hill
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo